PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
Phase 1
Recruiting
- Conditions
- Locally Advanced/Metastatic Solid Tumors
- Interventions
- Drug: PE0116&PE0105
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Shanghai HyaMab Biotech Co.,Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05801237
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
PE0116 Injection in Treatment of Patients With Advanced Solid Tumours
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Shanghai HyaMab Biotech Co.,Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT05800249
- Locations
- 🇨🇳
复旦大学附属中山医院, Shanghai, China
HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Shanghai HyaMab Biotech Co.,Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT04914351
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Orlando, Florida, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸Texas Oncology, Tyler, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath